MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey

Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Myeloma (SMM), and Multiple Myeloma Patient Experience With COVID-19 Survey

The purpose of this study is to examine how patients with multiple myeloma (MM) have been impacted by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.

The study will use a questionnaire to further understand how patients are being affected and gather information in order to track the long-term effects of the coronavirus.

The scope of the questionnaire will include, COVID-19 diagnosis and treatment, changes in myeloma treatment and care, clinical trial familiarity, health and fitness, and quality of life.

This questionnaire is a follow-on to the "MM and COVID-19" questionnaire.

Inclusion Criteria:

• Adult patients (greater than 18 years) diagnosed with MGUS, smoldering myeloma, and multiple myeloma.
• Access to a computer or electronic device with internet access, or phone
• Willing to create a patient profile on the HealthTree Cure Hub For Multiple Myeloma
• Willing to give electronically-signed consent
• Ability to read questions in English